Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta‐analysis
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17448 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Tsen-Fang Tsai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Asian People, Psoriasis, Severity of Illness Index. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb.
Abstract (Originalsprache)
Expanding the systemic treatment options for patients with psoriasis, deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor is approved in the United States, European Union, China, Japan, Taiwan, Korea, and other countries for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients. This systematic review and network meta‐analysis (NMA) evaluated the clinical efficacy associated with deucravacitinib and other biologic or non‐biologic systemic treatments for moderate to severe plaque psoriasis in Asian populations. Electronic databases were searched to identify randomized trials of the interventions of interest. Multinomial random effects models adjusting for baseline placebo risk were used to estimate Psoriasis Area and Severity Index (PASI) responses at weeks 10–16. Of 8596 studies identified, 20 were included in the NMA. The estimated PASI 75 and 90 (95% credible interval) response rates for deucravacitinib were estimated to be 66% (49%–80%) and 40% (24%–58%) in Asian populations, notably higher than placebo (6% [4%–9%] and 1% [0.8–2%]) and apremilast (24% [12%–40%] and 9% [4%–20%]). No statistically significant difference was observed in PASI 75 and 90 responses between deucravacitinib and adalimumab, certolizumab pegol, infliximab, ustekinumab, and tildrakizumab. Deucravacitinib demonstrated robust efficacy in the Asian population, with PASI 75 and 90 responses comparable to some biologics. Deucravacitinib provides a convenient oral therapy with efficacy similar to several biologic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
- Global Medical Affairs, Bristol Myers Squibb, Taipei, Taiwan.
- Worldwide HEOR, Bristol Myers Squibb, Princeton, New Jersey, USA.
- Evidera, Evidence Synthesis, Modeling and Communication, Waltham, Massachusetts, USA.
- Evidence Synthesis, Modeling and Communication, PPD Poland, Warsaw, Poland.
ORCID-Profile: Tsen-Fang Tsai, Yu-Huei Huang, Xing-Hua Gao, Seong-Jin Jo, April W Armstrong
Förderung
- Bristol Myers Squibb
- Bristol-Myers Squibb
Zitieren
APA
Tsai, T. F., Tada, Y., Kung, C., Zhong, Y., Cichewicz, A., Borkowska, K., Westley, T., Kisa, R. M., Huang, Y. H., Gao, X. H., Jo, S. J., & Armstrong, A. W. (2024). Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta‐analysis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17448
Vancouver
Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, et al. Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta‐analysis. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17448
BibTeX
@article{Tsai2024,
author = {Tsai, Tsen-Fang and Tada, Yayoi and Kung, Camy and Zhong, Yichen and Cichewicz, Allie and Borkowska, Katarzyna and Westley, Tracy and Kisa, Renata M and Huang, Yu-Huei and Gao, Xing-Hua and Jo, Seong-Jin and Armstrong, April W},
title = {Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta‐analysis},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17448}
}
EUVIMED